Cyclin A1 shows age-related expression in benign tonsils, HPV16-dependent overexpression in HNSCC and predicts lower recurrence rate in HNSCC independently of HPV16 by Weiss, D. (Daniel) et al.
Weiss et al. BMC Cancer 2012, 12:259
http://www.biomedcentral.com/1471-2407/12/259RESEARCH ARTICLE Open AccessCyclin A1 shows age-related expression in benign
tonsils, HPV16-dependent overexpression in
HNSCC and predicts lower recurrence rate in
HNSCC independently of HPV16
Daniel Weiss*, Mario Koopmann, Türker Basel and Claudia RudackAbstract
Background: Promoter methylation of the tumor suppressor gene Cyclin A1 could be associated with Human
Papillomavirus 16 (HPV16) induced Head and Neck Squamous Cell Carcinoma (HNSCC) and Cervical Carcinoma.
There is disagreement about the impact of this epigenetic event on protein expression of Cyclin A1 in malignant
and non-malignant tissue and there hardly exists any information about possible relationships between Cyclin A1
expression and clinicopathological characteristics in HNSCC.
Methods: We analyzed protein expression of Cyclin A1 in 81 HNSCC and 74 benign tonsils by
immunohistochemistry and correlated it to Cyclin A1 methylation status, presence of HPV16 infection and other
clinicopathological characteristics.
Results: Overexpression of Cyclin A1 was more present in HNSCC than in tonsils (p< 0.001). In both entities, HNSCC
and benign tonsils, expression of Cyclin A1 significantly correlated with the expression of Cyclin-dependent
kinase-inhibitor p16 (p = 0.000672 and 0.00495). In tonsils, expression of Cyclin A1 was inversely proportional to age
(p = 0.00000396), and further correlated with expression of tumor suppressor gene p53 (p = 0.000228). In HNSCC
Cyclin A1 expression was associated with the presence of HPV16 DNA (p = 0.0014) and a lower recurrence rate in
univariate and multivariate analysis (p = 0.002 and 0.013). Neither in HNSCC nor in tonsils Cyclin A1 expression
correlated with promoter methylation.
Conclusions: Cyclin A1 is an important cell cycle regulator with age-related increased expression in tonsils of
children. HPV16 induces overexpression of Cyclin A1 in HNSCC despite promoter methylation. Overexpression of
Cyclin A1 predicts a lower recurrence rate in HNSCC independently of HPV16.
Keywords: Head and neck squamous cell carcinoma, Cyclin A1, Promoter methylation, Human Papillomavirus 16.Background
In all types of tumors the cell cycle is an important tar-
get for both tumor progression and anti-tumor therapy.
Activators and inhibitors are regulating the cell cycle
through Cyclin-dependent kinase (CDK) complexes that
catalyze the ordered transition from one phase of the
cell cycle to the next [1]. The two known gene families
of CDK inhibitors are the cip/kip and the INK4a/ARF* Correspondence: daniel.weiss@ukmuenster.de
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reproduction in any medium, provided the orfamily. The cip/kip family includes the genes p21, p27
and p57, which modulate the activity of, inter alia, the
Cyclin A-CDK complex [2].
There are two A-type Cyclins, Cyclin A1 and Cyclin
A2. Both factors associate with CDK2, whereby Cyclin
A2 is essential for DNA replication and proliferation in
somatic cells and Cyclin A1 is highly expressed in testis
and expressed at low levels in most other tissues [3,4].
Cyclin A1 could bind to important cell cycle regulators:
the Rb family of proteins, the transcription factor E2F-1,
and the p21 family of proteins [4]. Cyclin A1 is required
for S phase and passage through G2 [5,6]. The disruptiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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E7 is sufficiently known. In this connection, the most
studied - and probably also the most important – cell
cycle targets are pRb and p53 [7]. However, HPV onco-
genes can also abuse other important cell cycle regula-
tors, like Cyclin A. Zerfass et al. could demonstrate that
HPV16-E7 can transform rodent fibroblasts through in-
duction of Cyclin A and E [8]. The transcription factor
E2F forms a complex with p107, Cyclin A, and the
CDK2 kinase (E2F-cyclin A complex) during S phase.
HPV16-E7 associates very efficiently with the E2F-Cyclin
A complex which is crucial for its transforming activity
[4,9]. Malanchi et al. could demonstrate that not only
HPV E7 but also E6 is able to promote G1/S transition
through increasing the activity of the Cyclin A/Cyclin-
dependent kinase 2 complex, which is involved in pRb
phosphorylation. This leads to an accumulation of pro-
teins that are negatively regulated by pRb, such as
p16IKN4a, CDC2, E2F-1 and Cyclin A [10,11].
Besides alcohol and nicotine abuse infection with
high-risk HPV is one of the most important risk factors
in the development of Head and Neck Squamous Cell
Carcinoma (HNSCC) [12-14]. Methylation of Cyclin A1
could be related to the presence of HPV16 DNA in
Head and Neck Squamous Cell Carcinoma (HNSCC)
and Cervical Neoplasia [15-17]. In cervical cancer Cyclin
A1 methylation could be associated with decreased pro-
tein expression and the integrated form of HPV. In con-
trast, we also found a higher frequency of Cyclin A1
promoter methylation in HNSCC, especially in HPV16
positive tumors, but could not attribute it to reduced
protein expression at first sight. We thought it was
partly due to the low sample size.
Santopietro et al. could identify protein expression of
Cyclin A as an independent predictor of high-risk HPV
and high-risk HPV associated high-grade lesions in cer-
vical cancer [18]. In renal, ovarian, and lung carcinoma
cells Cyclin A1 could be identified as a downstream tar-
get of p53 that mediates apoptosis, G2/M arrest, and mi-
totic catastrophe if up-regulated [19,20]. An inverse
correlation between Cyclin A1 methylation and p53 mu-
tation in HNSCC could be shown by Tokumaru et al.Figure 1 Immunohistochemical staining of Cyclin A1 (a), p16 (b) and p
HPV16 positive; Cyclin A1 overexpression (category 8); P16 overexpression (c[21]. Both research groups did their analysis without tak-
ing into account the HPV-status of cells. In our HNSCC
collective we found a p53-independent influence of
HPV16 on promoter methylation of Cyclin A1 [15].
In this study we wanted to establish the impact of Cyc-
lin A1 expression on clinicopathological parameters in
HNSCC. By including a larger sample size we intended
to re-evaluate the relationship between HPV16 and Cyc-
lin A1.
Results
Immunohistochemical expression of Cyclin A1 in HNSCC
and controls
In a first step we determined Cyclin A1 expression in
HNSCC (Figure 1a) and controls (benign tonsils,
Figure 2a) through immunohistochemistry by three in-
dependent pathologists and categorized it into eleven
different staining intensities (Table 1). On the basis of
the expression results in tonsils and due to lack of reli-
able data in literature we set the cut-off for considering
a Cyclin A1 overexpression at ≥ 20% positive cells.
Dependent (Chi-square test) or independent (Rank Sum
Test) of a cut-off, the expression of Cyclin A1 was much
more intense in HNSCC compared to tonsils (p< 0.001).
Due to disease-related epidemiology controls were much
younger than patients with HNSCC (p< 0.001).
Prevalence of HPV16 DNA, overexpression of p16 or p53,
and p53 mutation in HNSCC and controls
In HNSCC we found 37 (46%) HPV16 positive samples
in Real-Time PCR (Table 1). Of those 37 HPV16 positive
tumors, seven showed no overexpression of p16. Real-
Time PCR revealed 44 HPV16 negative samples,
whereby four samples showed an overexpression of p16.
These samples were further analyzed for other HPV
types by in-situ hybridization but remained HPV nega-
tive. When looking at the results broken down by pri-
mary site, tumors of the oropharynx (tonsil and base of
the tongue) showed a substantially higher frequency of
HPV16 and p16 overexpression compared to non-
oropharyngeal site (p< 0.001 and p = 0.008, Table 2). On
the other hand tumors originating from the anterior53 (c) in HNSCC. Tumor of a 77 year old man; primary site: tonsil;
ategory 9); P53 negative (category 1); original magnification: x50.
Figure 2 Immunohistochemical staining of Cyclin A1 (a), p16 (b) and p53 (c) in a benign tonsil. Tonsil of a 41 year old man; HPV16
negative; Cyclin A1 overexpression (category 4); P16 category 2; P53 category 2; original magnification: x50.
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quency of HPV16 (p = 0.035). Overexpression and muta-
tion of p53 could be detected in 33 of 80 and 19 of 41Table 1 Results of HPV16 RT-PCR, immunohistochemistry of p
Age (mean± sd)
Sex Male
Female
Cyclin A1 overexpression (abs./%) Total
Category 0 (negative)
Category 1 (few positive cells)
Category 2 (< 10%)
Category 3 (10-20%)
Category 4 (20-30%)
Category 5 (30-40%)
Category 6 (40-50%)
Category 7 (50-60%)
Category 8 (60-70%)
Category 9 (70-80%)
Category 10 (80-90%)
Category 11 (90-100%)
HPV16 positive (abs./%) Total
P16 positive
Cyclin A1 positive
HPV16 negative (abs./%) Total
P16 positive
Cyclin A1 positive
P16 overexpression (abs./%) Total
HPV16 negative
P53 overexpression (abs./%) Total
HPV16 positive
P53 mutation (abs./%) Total
HPV16 positive
P53 positive
Cut off for overexpression in immunohistochemistry: CDKN2A/p16 positive: ≥20% (c
(category ≥3).tumor samples. Interestingly, four HPV16 positive
tumors showed p53 mutation but no p53 overexpression
and four HPV16 negative tumors showed overexpression16, Cyclin A1, and p53 and p53 mutation analysis
HNSCC (N=81) Controls/Tonsils (N= 74) P
62.78 ± 11.24 27.19 ±19.26 <0.001
53 40 0.200
28 34
24/29.6 4/5.4 <0.001
0/0.0 2/2.7
4/4.9 9/12.2
25/30.9 34/45.9
28/34.6 25/33.8
14/17.3 4/5.4
5/6.2 0/0.0
3/3.7 0/0.0
1/1.2 0/0.0
1/1.2 0/0.0
0/0.0 0/0.0
0/0.0 0/0.0
0/0.0 0/0.0
37/45.7 0/0.0
29 out of 37/78.4
18 out of 37/48.6
44/54.3 74/100.0
4 out of 44/9.1 0 out of 74/0.0
6 out of 44/13.6 4 out of 74/5.4
33 out of 79/41.8 0/0.0
4 out of 33/12.1
33 out of 80/41.3 0/0.0
4 out of 33/12.1
19 out of 41/46.3 0 out of 30/0.0
4 out of 19/21.1
9 out of 19/47.4
ategory ≥4); Cyclin A1 positive: ≥20% (category ≥4); p53 positive: ≥10%
Table 2 Prevalence of HPV16 positivity in Real-Time PCR and overexpression of p16 in immunohistochemistry with
respect to primary site
Primary site N HPV16 positive RT-PCR P16 overexpression
abs. % P abs. % P
Tonsil 33 19 57.6 0.112 15/32* 46.9 0.492
Base of the tongue 28 17 60.7 0.062 15/27* 55.6 0.094
Oropharynx (Tonsil and base of the tongue) 61 36 50.0 < 0.001 30/59* 50.8 0.008
Anterior two-thirds of the tongue 9 1 11.1 0.035 2 22.2 0.291
Floor of the mouth 2 0 0.0 0.498 0 0.0 0.507
Hypopharynx 1 0 0.0 1.000 0 0.0 1.000
Soft palate 2 0 0.0 0.498 0 0.0 0.507
Supraglottic 3 0 0.0 0.246 1 33.3 1.000
Unknown (CUP) 3 0 0.0 0.246 0 0.0 0.261
*P16 immunohistochemistry was done in 79 of 81 cases.
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tumors with p53 mutation demonstrated overexpression
of the associated protein in immunohistochemistry.
In tonsils we could not find any positive samples
regarding HPV16 Real-Time PCR, overexpression of p16
and overexpression of p53. P53 mutation analysis
revealed only wild-type samples.
Correlation of Cyclin A1 expression with
clinicopathological parameters in controls
In benign tonsils the expression of Cyclin A1 was in-
versely proportional to age (p = 0.00000396) (Table 3).
Tissue sections from patients with daily nicotine con-
sumption showed significantly lower expression rates
than those of patients without nicotine abuse (p = 0.012).
The expression of Cyclin A1 showed weak but significant
correlation with the protein expression of p16
(p = 0.00495) and p53 (p = 0.000228).
Correlation of Cyclin A1 expression with
clinicopathological parameters in HNSCC
In HNSCC expression of Cyclin A1 significantly corre-
lated with HPV16-status (p = 0.001), with higher expres-
sion rates in HPV16 positive samples, but not with theTable 3 Correlation of Cyclin A1 expression in immunohistoch
controls (tonsils)
Clinicopathological parameter N Performed Stati
Age [y] 74 Spearman Rank O
Sex 74 Mann–Whitney R
Nicotine abuse 74 Mann–Whitney R
Alcohol abuse 74 Mann–Whitney R
P16 Expression 74 Spearman Rank O
P53 Expression 74 Spearman Rank O
Cyclin A1 Methylation 12 Mann–Whitney R
N: number of available samples; Age in years [y].copy number of E6 and E7 DNA (Table 4). Like in ton-
sils, the comparison of expression of Cyclin A1 and p16
revealed a relevant positive correlation between both
variables (p = 0.000672). We could not find any correl-
ation between the expression of Cyclin A1 and the ex-
pression or mutation of p53. If correlated with other
clinicopathological parameters, Cyclin A1 expression
showed no significant correlation with age, sex, primary
site, tumor size, metastatic spread, Grading, UICC stage
or alcohol and nicotine abuse (Table 4). As demon-
strated earlier, Cyclin A1 promoter methylation had no
impact on Cyclin A1 protein expression (p = 0.882) [15].
However, samples of HNSCC patients without locoregio-
nal recurrence showed significantly higher Cyclin A1 ex-
pression than those of patients with locoregional
recurrence (p = 0.002). This positive impact on the pro-
gression of the disease had no influence on survival,
since we could not find improved progression-free or
overall survival in patients with overexpression of Cyclin
A1 in associated samples. As expected, patients with
HPV16 positive tumors had improved progression-free
and improved overall survival (p = 0.017 and p = 0.018)
(data not shown). We could also detect significantly
more HPV16 positive samples in the group of patientsemistry with clinicopathological characteristics in
stic Subgroups P
rder σ=−0.512 0.000004
ank Sum male vs. female 0.899
ank Sum nicotine vs. no nicotine 0.012
ank Sum alcohol vs. no alcohol 0.160
rder σ= 0.336 0.005
rder σ= 0.419 0.0002
ank Sum methylated vs. non-methylated 0.386
Table 4 Correlation of Cyclin A1 expression in immunohistochemistry with clinicopathological characteristics in HNSCC
Clinicopathological parameter N Performed Statistic Subgroups P
Age [y] 81 Spearman Rank Order σ=−0.070 0.532
Sex 81 Mann–Whitney Rank Sum male vs. female 0.964
Primary site
Tonsil 33 Fisher exact CCNA1 <4 vs. ≥4 0.623
Base of the tongue 28 Fisher exact CCNA1 <4 vs. ≥4 0.447
Anterior two-thirds of the tongue 9 Fisher exact CCNA1 <4 vs. ≥4 0.268
Floor of the mouth 2 Fisher exact CCNA1 <4 vs. ≥4 1.000
Hypopharynx 1 Fisher exact CCNA1 <4 vs. ≥4 1.000
Soft palate 2 Fisher exact CCNA1 <4 vs. ≥4 1.000
Supraglottic 3 Fisher exact CCNA1 <4 vs. ≥4 0.551
Unknown (CUP) 3 Fisher exact CCNA1 <4 vs. ≥4 0.208
T 72 Fisher exact T1/2 vs. T3/4 0.591
N 73 Fisher exact N0/1 vs. N2/3 0.312
M 75 Fisher exact M0 vs. M1 0.094
G 62 Fisher exact G1/2 vs. G3/4 0.404
UICC stage 71 Fisher exact stage1/2 vs. stage3/4 1.000
Recurrence rate 64 Mann–Whitney Rank Sum Recurrence vs. no recurrence univariate 0.002
multivariate 0.013
Secondary tumor 78 Mann–Whitney Rank Sum sec. tumor vs no sec. tumor 0.516
Nicotine abuse 79 Mann–Whitney Rank Sum nicotine vs. no nicotine 0.358
Alcohol abuse 79 Mann–Whitney Rank Sum alcohol vs. no alcohol 0.743
Progression free survival 81 Kaplan-Meier CCNA1 <4 vs. ≥4 0.363
Overall survival 81 Kaplan-Meier CCNA1 <4 vs. ≥4 0.354
HPV16 DNA status 81 Mann–Whitney Rank Sum HPV16+ vs. HPV16- 0.001
E6 quantitative 37 Spearman Rank Order σ= 0.229 0.172
E7 quantitative 37 Spearman Rank Order σ= 0.250 0.134
P16 Expression 79 Spearman Rank Order σ= 0.376 0.0007
P53 Expression 80 Spearman Rank Order σ=−0.086 0.448
P53 Mutation 41 Mann–Whitney Rank Sum P53 mutated vs. wild-type 0.920
Cyclin A1 Methylation 44 Mann–Whitney Rank Sum methylated vs. non-methylated 0.882
N: number of available samples; CUP: Carcinoma of unknown primary; Age in years [y]; stage: UICC-stage; T: Tumor size: T1 (< 2 cm), T2 (2-4 cm), T3 (> 4 cm), T4
(Tumor infiltrates adjacent structures); N: status of regional lymph node metastasis: N0 (no metastasis), N1 (single ipsilateral lymph node metastasis, size< 3 cm),
N2a (single ipsilateral lymph node metastasis, size 3-6 cm), N2b (multiple ipsilateral lymph node metastases, size 3-6 cm), N2c (multiple ipsi- and contralateral
lymph node metastases, size 3-6 cm), N3 (lymph node metastasis, size> 6 cm); E6/E7 quantitative: results of quantitative HPV16 Real-Time PCR; CCNA1: Cyclin A1;
CCNA1 <4/≥4: immunohistochemical expression of Cyclin A1 less than 20% or at least 20%.
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proportional-hazards regression overexpression of Cyclin
A1 represented an independent prognostic risk factor for
lower recurrence rate (p = 0.013).
Discussion
We were the first to describe a connection between
HPV16 and Cyclin A1 promoter methylation in HNSCC
[15]. In contrary to other reports, we could show in this
context that the promoter methylation of Cyclin A1 does
not lead to a measurable impact on its protein expres-
sion and that the relationship between HPV16 andCyclin A1 methylation is independent of the expression
or mutation of p53 [19-21]. This time, we wanted to
solve the jigsaw puzzle of HPV16 and Cyclin A1 a little
more by analyzing the protein expression of Cyclin A1
in HPV16 positive and HPV16 negative HNSCC as well
as in benign tonsils in a greater collective. We were
further interested in detecting possible relationships
between protein expression of Cyclin A1 and clini-
copathological characteristics in malignant and non-
malignant oropharyngeal tissue. The results obtained by
these investigations showed a strong correlation between
Cyclin A1 protein expression and HPV16 in HNSCC. To
Table 5 Primers and probes used for HPV16-Real-Time PCR
Gene Sequence (5’! 3’)
HPV16 E6 Primer1, forward CTGCAATGTTTCAGGACCCA
Primer2, reverse TCATGTATAGTTGTTTGCAGCTCTGT
Probe FAM-AGGAGCGACCCAGAAAGTTACCACAGTT-TAMRA
HPV16 E7 Primer1, forward AAGTGTGACTCTACGCTTCGGTT
Primer2, reverse GCCCATTAACAGGTCTTCCAAA
Probe FAM-TGCGTACAAAGCACACACGTAGACATTCGTA-TAMRA
HBB Primer1, forward GTGAAGGCTCATGGCAAGAAAG
Primer2, reverse CAGCTCACTCAGTGTGGCAAAG
Probe FAM-ATGGCCTGGCTCACCTGGACAACC-TAMRA
PCR: Polymerase chain reaction; HPV16: Human Papillomavirus 16; E6, E7: Oncogenes of HPV16; HBB: Human beta-globin.
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depended more on the protein expression of p16 than on
the copy number of E6 and E7. It is assumed that Cyclin
A1 is induced by HPV16-E7 [4,8,9]. But, it could be
proven that also the E6 oncogene of high and low risk
HPV types is able to generate elevated Cyclin A1 expres-
sion through phosphorylation of pRb. Santopietro et al.
could identify protein expression of Cyclin A as inde-
pendent predictor of high-risk HPV and high-risk HPV
associated high-grade lesions in cervical cancer [18]. In
cervical cancer no correlation was found between the
quantity of HPV (determined by the proportion of HPV
L1 and histone acetyltransferase – a human housekeep-
ing gene) and Cyclin A1 promoter methylation [17]. Yet,
the physical state of HPV did affect methylation of Cyclin
A1; the integrated form of HPV had a significantly higher
impact on Cyclin A1 methylation than the episomal form.
We did not differentiate between integrated and episo-
mal form of HPV in our HNSCC collective. It remains
unclear if HPV16 induces promoter methylation or over-
expression of Cyclin A1 or both. Sartor and colleagues
could determine a higher methylation frequency and a
lower protein expression of Cyclin A1 in HPV positive
HNSCC than in HPV negative HNSCC [22]. They com-
pared the methylation patterns and expression differ-
ences of various genes in one HPV16 positive cell line,
two HPV negative cell lines and CaSki cells. What if
HPV16 causes both, Cyclin A1 promoter methylation
and Cyclin A1 protein overexpression? This would enable
the virus to down regulate the tumor suppressive proper-
ties of Cyclin A1 on the one hand and to have neverthe-
less the possibility of promoting cell cycle progression
through Cyclin A1 on the other hand. This exciting the-
ory needs further clarification. Continuing experiments
are already planned by our study group, particularly also
because our results regarding Cyclin A1 methylation and
p53 mutation are still limited by small sample size. Re-
gardless of HPV, we could identify Cyclin A1 as an inde-
pendent risk factor of a lower recurrence rate in HNSCC.Nevertheless, overexpression of Cyclin A1 did not have
any impact on survival. Methylation of Cyclin A1, along
with DCC and CDKN2A, has been found to predict
longer disease-free survival in HNSCC [23]. In our col-
lective, patients with Cyclin A1 promoter methylation in
their corresponding tumor samples tended to have
improved progression-free and overall survival but with-
out statistical significance (data not shown). Interestingly,
Cyclin A1 showed an age-related expression in tonsils.
Younger patients, especially children under the age of 18
had markedly higher expression rates in corresponding
tissue sections than older patients. We guess, that the
increased expression of Cyclin A1 in tonsils of little chil-
dren reflects the enhanced immunological activity taking
place in tonsils of patients in this age. This hypothesis is
confirmed by the following facts: first, the expression of
Cyclin A1 was almost invariably found inside the centre
of the lymphoid follicles of tonsils and, secondly, that the
expression correlated with those of other markers for a
heightened cell division rate, such as p16 and p53. The
elevated expression of Cyclin A1 in tonsils of non-
smokers could be due to the diminished or absent nico-
tine consumption in children. Because of epidemiological
reasons controls were much younger than patients with
HNSCC in our study. But, if we would redo the analysis
of Cyclin A1 protein expression with an age-matched
control group, the statistical difference between both
groups would become even larger.
Conclusions
Taken together, the findings obtained in our study
clearly demonstrate a linkage between HPV16 and Cyc-
lin A1 in HNSCC in one way or another. If the
enhanced methylation frequency of Cyclin A1 found in
HNSCC and Cervical Cancer is directly caused by the
HP-virus and the overexpression of Cyclin A1 is only an
indirect consequence of the altered cell cycle needs to
be proven in further experiments. Irrespective of the re-
lationship with HPV16 shown herein, Cyclin A1
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should therefore be considered as a possible tumor
marker.
Methods
Patients and controls
We screened fresh-frozen tissue sections and formalin-
fixed, paraffin-embedded tissue blocks of altogether 81
HNSCC from patients diagnosed and treated at the De-
partment of Otorhinolaryngology, Head and Neck Sur-
gery of the University Hospital of Münster, Germany.
Patients’ age ranged from 30 to 89 years (mean: 62.78,
standard deviation: 11.24 years). Fifty-three males and
28 females were included in the study (Table 1). Histo-
logical diagnose was based on examination of
hematoxylin and eosin-stained tissue sections by at least
two independent pathologists according to the World
Health Organization Classification of Tumors [24]. The
clinical data was abstracted from the patient’s medical
chart. Preoperative evaluation included an endoscopy of
the entire pharynx, larynx, trachea, bronchi and esopha-
gus, a CT-scan of the head and neck, of the thorax and
abdomen. Patients with lymph node metastasis but un-
known primary (CUP) were referred to a F-18-
fluordeoxyglucose positron emission tomography. In
case of undetectable primary tumor these patients add-
itionally received bilateral tonsillectomy and “blind” bi-
opsies of the tongue base and epipharynx. All HNSCC
were screened for HPV16 DNA in Real-Time PCR and
expression of CDKN2A/p16, Cyclin A1/CCNA1, and p53
in immunohistochemistry. Analysis of Cyclin A1 pro-
moter methylation and p53 mutation was done in 44
and 41 of these cases, respectively. The small sample
sizes in both analyses are due to DNA fragmentation in
Formalin-fixed paraffin-embedded tissue, which limits
the amount of usable results.
Fresh frozen tissue sections from tonsils of 74 patients,
which underwent tonsillectomy because of chronic ton-
sillitis or hyperplasia, were taken as controls (age:
27.19 ± 19.26 years; 34 females; 40 males) (Table 1). The
study protocol was reviewed and approved by the ethics
committee of the University of Münster, Germany, and
informed consent was obtained from all patients.
Quantitative HPV16 E6/E7 Real-Time PCR and HPV in-situ
hybridization
Detection of HPV16 through Real-Time PCR and immu-
nohistochemistry for CDKN2A/p16 was done as
described previously [25]. Briefly, tissue sections (20-μm)
were cut and deparaffinized, and DNA was extracted
using a commercial kit (QIAamp DNA Mini Kit). Real-
time PCR was performed using ABI Prism 7900HT Se-
quence Detection System and the TaqMan Genotyping
PCR Master Mix (Applied Biosystems) (Table 5). Beta-globin, a human housekeeping gene was used as an indi-
cator for successful extraction of an equivalent length of
target viral DNA. Serial dilutions of DNA isolated from
cervical carcinoma cell line CaSki (ATCC-CRL-1550,
500 integrated HPV16 copies) were run in parallel as
controls.
Tumors which were negative in the HPV16 Real-Time
PCR but showed high p16 expression were analyzed for
presence of other HPV types by in-situ hybridization
using the DNP-labelled genomic HPV probe sets IN-
FORM HPV II Family 6 (HPV types 6, 11, 40, 42, 43, 44,
54, 61, 70, 72, 81) and HPV III Family 16 (HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, 82)
(both from Ventana, Mannheim, Germany) and the
automated Benchmark system (Ventana) according to
the instructions of the provider. Briefly, 4 μm sections
were deparaffinized, pre-treated with Protease 3, hybri-
dized with both probe cocktails and stringently washed.
Bound probes were subsequently detected by sequential
incubation with anti-DNP antibodies, anti-Ig/Biotin,
streptavidin bound alkaline phosphatase and BCIP. Pre-
viously analysed cervical biopsies were included as posi-
tive controls for both probe sets.
Quantitation of HPV16 E6 and E7 DNA using Real-Time
PCR
For Real-Time DNA Quantitation we generated two
standard curves, one for determination of absolute DNA
amount and one for calculation of E6 and E7 DNA
amount [26]. The standard curve for absolute DNA
amount was generated by amplification of β-globin using
known amounts of genomic DNA from a healthy human
individual (200.0 ng, 20.0 ng, 2.0 ng, and 0.2 ng; Pro-
mega, Madison, WI). The second standard curve for E6
and E7 DNA was generated by using known amounts of
E6 or E7 PCR products obtained from CaSki cell DNA
(1x108 copies, 1x106 copies, 1x104 copies, and 1x102
copies). The copy number of E6 or E7 DNA of tumor
samples was determined by linear extrapolation of the
E6 or E7 CT values of tumor samples, using the equa-
tion of the line obtained from the absolute E6 or E7
standard curve, and dividing these values by the relative
amounts of β-globin.
Immunohistochemical analysis of Cyclin A1, CDKN2A/p16
and p53
For immunohistochemical analysis of Cyclin A1,
CDKN2A/p16 and p53 protein expression four
micrometer-thick sections sliced from paraffin-
embedded HNSCC specimens were deparaffinized by
Xylene and subjected to antigen retrieval by microwav-
ing in 10 mmol/L of sodium citrate for 30 minutes. The
sections were incubated with a monoclonal mouse anti-
human Cyclin A1 antibody (6E6, Novocastra Laboratory,
Table 6 Primers and probes used for p53 mutation
analysis
Exon Primer Sequences (5’! 3’) Annealing
Temperature (°C)
2-4 A1 forward TCAGACACTGGCATGGTGTTG 64
reverse AGGGTGAAGAGGAATCCCAAAG
A2 forward GTGAGTGGATCCATTGGAAG 64
reverse GTGAAAAGAGCAGTCAGAGG
5/6 B forward TAGTGGGTTGCAGGAGGTGC 62
reverse GAGGCCCTTAGCCTCTGTAAGC
7 C forward CTGCTTGCCACAGGTCTCC 62
reverse CGGGGATGTGATGAGAGGTGG
8/9 D forward AAGGACAAGGGTGGTTGGGAG 62
reverse CAACCAGGAGCCATTGTCTTTG
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mouse anti-human p53 antibody (DO-7, DakoCytoma-
tion, Glostrup, Denmark) for 60 min and 25 min, re-
spectively, and stained by DAKO LSAB™+/HRP kit (No.
K 0679, Dako, Glostrup, Denmark). For immunohisto-
chemistry of p16 (the protein encoded by CDKN2A) the
CINtec® Histology Kit (mtm laboratories, Heidelberg,
Germany) was used. For verification of specifity of stain-
ing an extra tissue section was stained with a monoclo-
nal mouse anti-Rat oxytocin-related neurophysin
antibody, as a negative control in each case. A HPV16-
positive tumor with high p16 expression was used as a
positive control. The results of immunohistochemistry
were based on examination of tissue sections by at least
three independent pathologists (L.B., T.B. and G.K.)
without knowledge of other clinicopathological data.
Hematoxylin and eosin staining was performed for refer-
ence. The specimens were viewed with a Leica DMLB
microscope. Strong nuclear staining was considered
positive for Cyclin A1 and p53 expression. P16 expres-
sion was scored as positive if strong and diffuse nuclear
and cytoplasmic staining was present (Figure 1 and 2).
Staining intensities were measured as the percentage of
positively stained cells or nuclei in ten randomly selected
fields (minimum of 1000 cells, 100x magnification). In
the event of divergent results from one investigator or
between investigators, the case was discussed again be-
tween the parties to find a consensus conclusion. In case
of persistent differences between them, the mean of the
three opinions was considered. The staining intensities
for all three proteins were scored from 0–11 and allo-
cated as follows: 0: negative specimens, 1: few positive
cells or nuclei, 2: less than 10% positive cells or nuclei,
3: 10-20% positive cells or nuclei, 4: 20-30% positive cells
or nuclei, 5: 30-40% positive cells or nuclei, 6: 40-50%
positive cells or nuclei, 7: 50-60% positive cells or nuclei,
8: 60-70% positive cells or nuclei, 9: 70-80% positive cells
or nuclei, 10: 80-90% positive cells or nuclei, 11: 90-100
% positive cells or nuclei. The cut-off for considering an
overexpression was deduced from the results of those
achieved for the benign tonsils and those of literature
[27-29]. They were in detail for the specific proteins:
CDKN2A/p16: ≥ 20% (IHC category ≥ 4), Cyclin A1/
CCNA1: ≥ 20% (IHC category ≥ 4), and p53: ≥ 10% (IHC
category ≥ 3).
Methylation specific Polymerase Chain Reaction
For methylation analysis of Cyclin A1 in tumor and con-
trol tissue the Methyl-Profiler™ DNA Methylation PCR
Array System (SABiosciences, Frederick, USA) was used.
This system can detect DNA methylation of up to 96
genes simultaneously with pre-designed primers but
without bisulfite conversion. DNA methylation-sensitive
and methylation-dependent restriction enzymes are usedto selectively digest unmethylated or methylated DNA,
respectively. The remaining DNA after digestion is
quantified by Real-Time PCR using primers that flank
the region of interest. The relative concentration of dif-
ferentially methylated DNA (specifically hypermethy-
lated, intermediately methylated, and unmethylated
DNA) are determined by comparing the amount in each
digest with that of a mock digest. The PCR cycling con-
ditions were as follows: 1 cycle at 95 °C for 10 minutes,
40 cycles including 15 seconds at 97 °C and 1 minute at
72 °C. The PCR product was marked with SYBR® Green.
According to the manufactures protocol the cut-off level
for significant promoter methylation should be defined
by the user. A sample or tumor can be defined as signifi-
cantly methylated, if the extent of hypermethylated
DNA reaches 10 to 20 percent irrespective of the inter-
mediately methylated fraction. However, this threshold is
dependent on the extent of non-target cell contamin-
ation. The greater the extent of contamination, the
higher the threshold must be set. We decided to set the
cut-off level at 20% to detect only the truly methylated
samples. Methylation analysis was done in 44 tumor and
12 control samples.
Mutation analysis of p53
DNA was extracted from tumor tissue and tonsils as
described above. Polymerase chain reaction (PCR) was
used to amplify the domain regions and flanking splice
sites of exons 2–9 of the p53 gene, using primer sets
and conditions described in Table 6. PCR was performed
in a 25 μl volume containing 200 ng of genomic DNA;
1xPCR buffer (Invitrogen, Burlington, Canada); 5 nmol
of each dCTP, dGTP, dTTP, and dATP; 1.5 mM MgCl2;
15pmol of each primer; and 1 U of Taq polymerase
(Invitrogen). The PCR conditions were 165 sec at 96 °C,
45 sec at appropriate annealing temperature and 9 min
at 72 °C. The PCR products were sequenced using the
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Foster City, CA, USA). P53 mutational status was esti-
mated in 41 HNSCC patients and 30 controls. Sequence
chromatograms were compared with the p53 reference
sequence in the IARC TP53 Mutation Database (www-
p53.iarc.fr) and/or the Single Nucleotide Polymorphism
(SNP) Database (www.ncbi.nlm.nih.gov/projects/SNP/).
Statistical analysis
The clinical and pathological data was analyzed by Fisher’s
exact test for categorical variables and Mann–Whitney test
for continuous variables. Possible correlation between
two continuous variables was analyzed by Spearman rank
order. Differences in survival probability were compared
by Kaplan-Meier LogRank, whereby death from any
cause was considered an event and data on patients
who were alive at the last follow-up contact were
censored. These analyses were performed using Sigma-
Plot software. Statistical significance was accepted at
p< 0.05.
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